Biopharmaceutical Excipients Market Report 2026

The biopharmaceutical excipients market size has grown strongly in recent years. It will grow from $3.27 billion in 2025 to $3.57 billion in 2026 at a compound annual growth rate (CAGR) of 9.2%. The growth in the historic period can be attributed to increasing biologic drug approvals, early adoption of protein stabilizers, growth in injectable formulations, expansion of vaccine development, advancements in formulation science.

The biopharmaceutical excipients market size is expected to see strong growth in the next few years. It will grow to $5.04 billion in 2030 at a compound annual growth rate (CAGR) of 9%. The growth in the forecast period can be attributed to increasing complexity of biologic formulations, rising demand for long shelf-life products, expansion of cell and gene therapies, growing regulatory focus on excipient safety, increasing investments in advanced drug delivery systems. Major trends in the forecast period include increasing demand for high-purity biologic excipients, growing use of multifunctional formulation ingredients, expansion of excipients for cell and gene therapies, rising focus on stability-enhancing compounds, enhanced customization of excipient solutions.

The rising need for vaccine development is set to boost the biopharmaceutical excipients market in the years ahead. Vaccine development involves crafting and formulating immunizations that protect against infectious diseases and enhance public health, depending on premium excipients to guarantee the stability, effectiveness, and safety of vaccine products. This surge in demand arises from worldwide efforts to combat infectious diseases, bolster public health readiness, and speed up research for quicker, more potent immunization options. Biopharmaceutical excipients are essential in vaccine formulations, as they stabilize antigens, improve solubility, and preserve product integrity throughout storage and transport. For example, in 2025, data from the Centers for Disease Control and Prevention - a U.S. national public health institute - showed adolescent vaccination rates for critical vaccines like tetanus, diphtheria, and acellular pertussis climbing from 89.9% in 2022 to 91.3% in 2024; meningococcal conjugate vaccine coverage advancing from 88.6% to 90.1%; and human papillomavirus vaccine coverage (at least two doses) jumping sharply from 76% to 92.6% during that time. Thus, the expanding demand for vaccine development is fueling expansion in the biopharmaceutical excipients market.

Major companies in the biopharmaceutical excipients market are prioritizing technological advancements, like ultra-high purity surfactants, to enhance protein stability, avoid degradation, and meet regulatory standards for injectable formulations. These ultra-high purity surfactants represent highly refined surface-active agents featuring very low impurity levels and uniform composition, crafted to deliver stability, safety, and reliability in delicate pharmaceutical and biopharmaceutical products. For example, in September 2025, Evonik Industries AG - a Germany-based chemicals firm - introduced MaxiPure Polysorbate 80 tailored for injectable and biopharmaceutical uses. This excipient boasts an oleic acid content over ninety-eight percent, outstanding clarity, and complete adherence to European Pharmacopoeia, United States Pharmacopoeia, Japanese Pharmacopoeia, and Chinese Pharmacopoeia requirements. It tackles key issues in protein stability, inhibits oxidative breakdown, facilitates reliable solubilization of hydrophobic active pharmaceutical ingredients, and boosts overall formulation dependability. Through this excipient, Evonik supports pharmaceutical and biopharmaceutical firms in efficiently creating advanced biologics and injectable treatments while upholding safety and compliance.

In May 2025, Roquette Frères, a France-based provider of pharmaceutical excipients, acquired International Flavors & Fragrances (IFF) Pharma Solutions for an undisclosed sum. This acquisition bolstered Roquette's pharmaceutical excipients portfolio by incorporating IFF Pharma Solutions’ specialized knowledge and innovative products, improving its capacity to offer high-value drug delivery options and aid the creation of sophisticated pharmaceutical formulations globally. International Flavors & Fragrances Inc., a US-based firm, supplies pharmaceutical excipients and functional ingredients via its IFF Pharma Solutions division, facilitating drug formulation and delivery in the biopharmaceutical excipients sector.

Major companies operating in the biopharmaceutical excipients market are The Archer-Daniels-Midland Company, BASF SE, The Dow Chemical Company, Mitsubishi Chemical Group Corporation, Novo Nordisk A/S, Associated British Foods plc, Merck KGaA, Asahi Kasei Corporation, Evonik Industries AG, Kerry Group plc, Wacker Chemie AG, Clariant AG, Shin-Etsu Chemical Co. Ltd., Roquette Frères, IMCD Group N.V., Croda International Plc, Ashland Global Holdings Inc., NOF Corporation, Colorcon Limited, J. Rettenmaier & Söhne GmbH + Co. KG, Spectrum Chemical Manufacturing Corporation, BioSpectra Inc., Sigachi Industries Limited, DFE Pharma, FUJIFILM Toyama Chemical Co. Ltd, Kirsch Pharma GmbH, Meggle Group GmbH, InVitria Inc., BOC Sciences Inc.

North America was the largest region in the biopharmaceutical excipients market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the biopharmaceutical excipients market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the biopharmaceutical excipients market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the biopharmaceutical excipients market by increasing costs of imported specialty chemicals, sugars, polymers, proteins, and formulation-grade raw materials used in biologic drug development. North America and Europe are most affected due to reliance on imported high-purity excipient inputs, while Asia-Pacific faces cost pressures in excipient export markets. These tariffs are raising formulation costs and influencing supplier selection strategies. However, they are also encouraging domestic excipient production, regional supplier diversification, and innovation in locally sourced pharmaceutical-grade excipients.

The biopharmaceutical excipients market research report is one of a series of new reports that provides biopharmaceutical excipients market statistics, including biopharmaceutical excipients industry global market size, regional shares, competitors with a biopharmaceutical excipients market share, detailed biopharmaceutical excipients market segments, market trends and opportunities, and any further data you may need to thrive in the biopharmaceutical excipients industry. This biopharmaceutical excipients market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Biopharmaceutical excipients serve as inactive components mixed with active pharmaceutical ingredients to support the creation, stability, and delivery of biologic drugs. They boost the efficacy, safety, and shelf-life of biopharmaceutical products without delivering any therapeutic effects of their own. These excipients consist of diverse compounds like sugars, polymers, and proteins that facilitate drug formulation and administration.

The primary categories of biopharmaceutical excipients include binders, coatings, diluents, disintegrants, lubricants and glidants, polyols, preservatives, solubilizers and surfactants or emulsifiers, and suspending and viscosity agents. Binders consist of materials incorporated into powders or granules within pharmaceutical, food, or material formulations to impart cohesion and structural stability to the finished product. Key types of biologics encompass antibodies, vaccines, cell therapies, and additional varieties. The diverse functionalities cover fillers and diluents, binders, suspending and viscosity agents, flavouring agents and sweeteners, coating agents, colourants, disintegrants, lubricants and glidants, and preservatives. The range of applications spans injectable formulations, oral formulations, topical formulations, transdermal formulations, and cell and gene therapies, serving various end users including biopharmaceutical companies and pharmaceutical companies, contract manufacturers, and research institutes.

The biopharmaceutical excipients market consists of sales of growth media, buffer solutions, stabilizers, cryoprotectants, preservatives, surfactants, salts, amino acids, sugars. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.